100706-药理学

抗肿瘤新药研发和作用机制研究
DNA损伤修复通路及核内蛋白的干预研究
靶向泛素蛋白酶体途径的新药研发

2007-09--2012-07   中国科学院上海药物研究所   博士
2003-09--2007-07   山东大学   本科

   

2019-10~现在, 中国科学院上海药物研究所, 研究员
2016-10~2019-09,中国科学院上海药物研究所, 副研究员
2016-02~2016-09,中国科学院上海药物研究所, 助理研究员
2012-09~2016-01,Weill Cornell Medicine, Postdoc
2007-09~2012-07,中国科学院上海药物研究所, 博士
2003-09~2007-07,山东大学, 本科

   

（ 1 ） 2-Aryl/heteroarylbenzofuran- 7-formamide compounds, preparation method and use thereof., 2015, 第 5 作者, 专利号: No. 2,863,988

（ 2 ） 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途。, 2015, 第 5 作者, 专利号: ZL 201210028895.0.

   

（1） Identification of YCH2823 as a novel USP7 inhibitor for cancer therapy, Biochem Pharmacol, 2024, 
（2） YCH1899, a Highly Effective Phthalazin-1(2 H)-one Derivative That Overcomes Resistance to Prior PARP Inhibitors, J Med Chem, 2023, 
（3） Identification of 1,2,4Triazolo4,3-apyrazine PARP1 inhibitors with overcome acquired resistance activities, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 第 15 作者  通讯作者
（4） Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance, EMBO MOLECULAR MEDICINE, 2023, 第 23 作者  通讯作者
（5） SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy, NEOPLASIA, 2022, 第 10 作者  通讯作者
（6） Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 第 11 作者
（7） Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold, JOURNAL OF MEDICINAL CHEMISTRY, 2021, 第 9 作者  通讯作者
（8） Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers, INVESTIGATIONAL NEW DRUGS, 2021, 第 12 作者  通讯作者
（9） Glycogen synthase kinase 3 beta inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer, CELL DEATH & DISEASE, 2021, 第 11 作者  通讯作者
（10） Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors, AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 第 6 作者  通讯作者
（11） Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity, INTERNATIONAL JOURNAL OF CANCER, 2019, 第 8 作者
（12） Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression, CANCER SCIENCE, 2018, 第 7 作者  通讯作者
（13） Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors, ACTA PHARMACOLOGICA SINICA, 2017, 第 11 作者  通讯作者
（14） Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution, ONCOTARGET, 2017, 第 1 作者
（15） Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials, CANCER LETTERS, 2017, 第 20 作者  通讯作者
（16） PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis, NATURE COMMUNICATIONS, 2016, 第 1 作者
（17） PTEN Regulates DNA Replication Progression and Stalled Fork Recovery, NATURE COMMUNICATIONS, 2015, 第 1 作者

   

（ 1 ） 靶向类泛素化修饰Neddylation治疗恶性肿瘤, 负责人, 国家任务, 2021-01--2024-12
（ 2 ） PARP抑制剂耐药分子机制和靶向药物研究, 负责人, 地方任务, 2019-04--2022-03
（ 3 ） 新一代PARP抑制剂的抗耐药作用及机制研究, 负责人, 国家任务, 2018-01--2021-12
（ 4 ） Akt信号通路调控PARP抑制剂抗肿瘤活性的机制研究, 负责人, 国家任务, 2017-01--2019-12
（ 5 ） 抗PARP抑制剂耐药新靶标的发现与确证, 负责人, 中国科学院计划, 2017-01--2018-12